Novartis initiates pediatric study for asciminib in Chronic Myeloid Leukemia
Novartis is conducting a study to evaluate the dose and safety of asciminib in pediatric patients with Chronic Myeloid Leukemia.
Asset / Drug
Drug and asset intelligence for asciminib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.